Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Regeneron Pharmaceuticals

Status

Conditions: Cutaneous Squamous Cell Carcinoma (CSCC); Non-Small Cell Lung Cancer (NSCLC); Basal Cell Carcinoma (BCC)

Treatments: Drug: Cemiplimab

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT06132191

R2810-Cemiplimab

Details and patient eligibility

About

Provide expanded access of cemiplimab in patients with solid tumors

Full description

Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria